Article

Pharmacological considerations for the proper clinical use of aminoglycosides.

Department of Pediatrics, Democritus University of Thrace Medical School, Alexandroupolis, Thrace, Greece.
Drugs (Impact Factor: 4.13). 12/2011; 71(17):2277-94. DOI: 10.2165/11597020-000000000-00000
Source: PubMed

ABSTRACT Aminoglycosides constitute one of the oldest classes of antimicrobials. Despite their toxicity, mainly nephrotoxicity and ototoxicity, aminoglycosides are valuable in current clinical practice, since they retain good activity against multidrug-resistant Gram-negative pathogens, such as Pseudomonas aeruginosa and Acinetobacter spp. Time-kill studies have shown a concentration-dependent and partially concentration-dependent bacterial killing against Gram-negative and Gram-positive bacteria, respectively. Pharmacodynamic data gathered over recent decades show that the administration of aminoglycosides by an extended-interval dosing scheme takes advantage of the maximum potential of these agents, with the goal of achieving an area under the concentration-time curve (AUC) of 100 mg · h/L over 24 hours and a peak plasma drug concentration (C(max)) to minimum inhibitory concentration (MIC) ratio of 8-10. Several clinical conditions that are common in seriously ill patients result in expansion of the extracellular space and can lead to a lower than desirable C(max) with the usual loading dose. Extended-interval dosing schemes allow adequate time to decrease bacterial adaptive resistance, a phenomenon characterized by slow concentration-independent killing. Adaptive resistance is minimized by the complete clearance of the drug before the subsequent dose, thus favouring the extended-interval dosing schemes. The efficacy of these schemes is also safeguarded by the observed post-antibiotic sub-MIC effect and post-antibiotic leukocyte enhancement, which inhibit bacterial regrowth when the serum aminoglycoside levels fall below the MIC of the pathogen. In everyday clinical practice, aminoglycosides are usually used empirically to treat severe sepsis and septic shock while awaiting the results of antimicrobial susceptibility testing. The European Committee on Antimicrobial Susceptibility Testing acknowledges the regimen-dependent nature of clinical breakpoints for aminoglycosides, i.e. of MIC values that classify bacterial isolates into sensitive or resistant, and bases its recommendations on extended-interval dosing. To a large extent, the lack of correlation between in vitro antimicrobial susceptibility testing and clinical outcome is derived from the fact that the available clinical breakpoints for aminoglycosides are set based on mean pharmacokinetic parameters obtained in healthy volunteers and not sick patients. The nephrotoxicity associated with once- versus multiple-daily administration of aminoglycosides has been assessed in numerous prospective randomized trials and by several meta-analyses. The once-daily dosing schedule provides a longer time of administration until the threshold for nephrotoxicity is met. Regarding ototoxicity, no dosing regimen appears to be less ototoxic than another. Inactivation of aminoglycosides inside the bacterial pathogens occurs by diverse modifying enzymes and by operation of multidrug efflux systems, making both of these potential targets for inhibition. In summary, despite their use for several decades, the ideal method of administration and the preferred dosing schemes of aminoglycosides for most of their therapeutic indications need further refinement. Individualized pharmacodynamic monitoring has the potential of minimizing the toxicity and the clinical failures of these agents in critically ill patients.

2 Followers
 · 
175 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 18% of patients undergoing cardiac surgery experience AKI (on the basis of modern standardized definitions of AKI), and approximately 2%-6% will require hemodialysis. The development of AKI after cardiac surgery portends poor short- and long-term prognoses, with those developing RIFLE failure or AKI Network stage III having an almost 2-fold increase in the risk of death. AKI is caused by a variety of factors, including nephrotoxins, hypoxia, mechanical trauma, inflammation, cardiopulmonary bypass, and hemodynamic instability, and it may be affected by the clinician's choice of fluids and vasoactive agents as well as the transfusion strategy used. The risk of AKI may be ameliorated by avoidance of nephrotoxins, achievement of adequate glucose control preoperatively, and use of goal-directed therapy hemodynamic strategies. Remote ischemic preconditioning is an exciting future strategy, but more work is needed before widespread implementation. Unfortunately, there are no pharmacologic agents known to reduce the risk of AKI or treat established AKI.
    Clinical Journal of the American Society of Nephrology 11/2014; 10(3). DOI:10.2215/CJN.07830814 · 5.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Aminoglycoside clearance depends on kidney function but the Australian Therapeutic Guidelines for antibiotics (version 14, 2010) recommend initial dosing based on weight without consideration of kidney function. Other guidelines which modify dosing based on kidney function estimates often use the Cockroft-Gault equation but the role of the estimated glomerular filtration rate equations for this purpose is unclear. We aimed to determine the performance of current guideline dosing in achieving target area-under-the-curve and examine the relative precision of the estimated glomerular filtration rate equations compared to traditional Cockroft-Gault creatinine clearance in predicting aminoglycoside clearance.Methods We analysed 496 aminoglycoside treatment episodes involving 1377 infusions in adult patients. Conformity with antibiotic guideline dosing was achieved if the discrepancy between prescribed and recommended dose was less than 15%. Aminoglycoside clearance was determined from linear regression using a one compartment model with the ALADDIN program. We assessed the precision of the Cockroft-Gault, MDRD and CKD-EPI equations in predicting aminoglycoside clearance by correlation and linear regression.ResultsConformity with guideline dosing was not associated with achieving target area-under-the-curve. The CKD-EPI estimated glomerular filtration rate adjusted for body surface area showed the highest correlation (gentamicin, r=0.66; tobramycin, r=0.82) and best predictive model for aminoglycoside clearance.Conclusion Current guideline dosing may be suboptimal for achieving target area-under-the-curve. The CKD-EPI equation adjusted for patient body surface area best predicts aminoglycoside clearance, and could be evaluated as a covariate in determining initial aminoglycoside dosing.
    Internal Medicine Journal 01/2015; 45(3). DOI:10.1111/imj.12684 · 1.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A highly reliable and accurate indirect competitive enzyme-linked immunosorbent assay (icELISA) was developed for the detection of streptomycin (STR) in animal-derived foods. The half-maximum inhibition concentration (IC50) of the icELISA for STR was 2.00 ng mL-1 and the limit of detection (LOD, calculated as the IC15 value) was 0.24 ng mL-1. The cross-reactivities with other aminoglycoside antibiotics were very low except for dihydrostreptomycin (95.50%). The recoveries for all samples at five levels (15, 30, 120, 300, 600 ng g-1) ranged from 71.32% to 106.94%. The coefficients of variation of intra- and inter-assays were below 14%. There was a good correlation (R2 = 0.9854) between the data determined by this ELISA and the commercial kit. The analysis of variance of the recoveries showed the sufficiently high stability of the assay to STR in eight animal-derived foods (chicken, pork, chicken liver, pig liver, pig kidney, fish, shrimp, and cow milk). The ELISA allows for a rapid, low-cost, sensitive and accurate determination of STR residues in animal-derived foods.
    Analytical methods 06/2013; 5(17):-. DOI:10.1039/C3AY40131F · 1.94 Impact Factor